Important clinical research questions in primary mediastinal large B-cell lymphoma (PMBL).
Can third-generation chemotherapy regimens be shown prospectively to be superior in the era of rituximab?
What is the role of PET scanning in determining cure following chemotherapy?
Can consolidative radiotherapy be omitted in selected individuals?
Can improved understanding of the biology of PMBL lead to rationally targeted novel therapies to improve outcomes for patients with refractory or relapsed disease?
Can third-generation chemotherapy regimens be shown prospectively to be superior in the era of rituximab?
What is the role of PET scanning in determining cure following chemotherapy?
Can consolidative radiotherapy be omitted in selected individuals?
Can improved understanding of the biology of PMBL lead to rationally targeted novel therapies to improve outcomes for patients with refractory or relapsed disease?